A randomized study of 200 HIV-positive pregnant women in Uganda found that the addition of monthly dihydroartemisinin-piperaquine to a daily regimen of trimethoprim-sulfamethoxazole did not reduce the risk of placental malaria. The findings were reported in the Journal of Infectious Diseases.
University of Pennsylvania investigators evaluated blood plasma samples from transplant recipients and found that modifications in donor exosomes can be an early indication of transplant rejection, according to research in the Journal of Clinical Investigation. The study was supported by the NIH.
BioLineRx reported that the interim results of an open-label, Phase II trial show that one injection of its BL-8040 drug candidate was as effective at mobilizing stem cells for transplantation as 4-6 doses of granulocyte colony-stimulating factor. The second part of the trial is scheduled to include 24 pairs of donors and recipients.
A new case of locally acquired Zika virus infection and four travel-related cases have been reported in Miami-Dade County, Fla. The CDC has confirmed the locally-acquired case in an asymptomatic individual who likely was infected in 2016 following multiple exposures to areas where mosquitoes were spreading the virus.
Researchers with the University of California at San Francisco reported in the journal Nature that mouse lungs produce the majority of platelets and are home to a reservoir of blood stem cells. Engineered fluorescent megakaryocytes in the lungs produced more than 10 million platelets an hour.
Sixty-seven percent of Ebola patients treated with interferon beta-1a survived at least 21 days, compared with 19% of other patients, according to a small, one-branch study in the journal PLOS One. Researchers also noted that the virus was cleared from the patients' blood faster when treated with interferon.
Purdue University researchers are developing technology to determine the presence of mosquito-borne viruses including Zika and West Nile outside the laboratory. The assay, which has been in development for five years, is being developed for use at the point of care and would possibly be available at drugstores, a researcher said.
Seres Therapeutics received positive feedback from the FDA on plans for a 24-week clinical trial of its Clostridium difficile infection therapy candidate SER-109.
Sandia National Laboratories has developed a low-cost mobile device that uses a smartphone app to identify the presence of Zika, dengue and other mosquito-borne diseases in blood, saliva and urine samples. The device uses loop-mediated isothermal amplification that, with the aid of custom biochemical agents and DNA "primer" molecules, indicates traces of the virus when the sample is heated and molecules fluoresce.